Delivery Order 75N94020D00015-75N94023F00001
- Not listed
- This federal contract was awarded by the National Institutes of Health's National Institute of Child Health and Human Development to Essential Access Health, a non-profit organization that champions and promotes quality sexual and reproductive health care. The contract is a Definitive Contract, Cost No Fee, with a Potential Value of $532,326.00. The contract does not have a Set-Aside designation. Under this contract, Essential Access Health has received several delivery orders to finalize...
- This is a delivery order awarded by the National Institute of Child Health and Human Development (NICHD), a civilian agency within the U.S. Department of Health and Human Services, to Essential Access Health (doing business as Cfhc), a non-profit organization. The $77,614 cost-no-fee contract tasks Essential Access Health to assist in developing new contraceptive products through protocol review, protocol development, and other activities related to the Contraceptive Clinical Trials Network....
- This federal contract award, with an ID of 75N94019D00004|75N94023F00003, was issued by the National Institute of Child Health and Human Development (NICHD), a civilian agency within the Department of Health and Human Services. The $2,160,831.00 delivery order was awarded to Health Decisions, Inc., a for-profit organization, to provide services including finalization, procurement of regulatory approval, and complete start-up activities for the Ovaprene vaginal device clinical trial. This order...
- The National Institute of Child Health and Human Development (NICHD) awarded a delivery order valued at $62,897 to Essential Access Health (doing business as CFHC) on August 1, 2020, with an ultimate completion date of July 31, 2026. This cost-no-fee delivery order supports the Contraceptive Development Program and specifically assists the NICHD Contraceptive Clinical Trials Network – Female Sites through protocol review, protocol development, and activities associated with past, present, and...
- The National Institute of Child Health and Human Development (NICHD), a civilian agency within the U.S. Department of Health and Human Services, has awarded a $176,019 delivery order to the Albert Einstein College of Medicine, a private non-profit educational institution, to perform services related to the Ovaprene Vaginal Device clinical trial. The contract, which has no set-aside designation, covers protocol finalization, regulatory approval, start-up, and commencement of recruitment,...
- This is a firm fixed price delivery order awarded by the National Institute of Child Health and Human Development (NICHD), a civilian agency under the Department of Health and Human Services, to Health Decisions, Inc. for the Contraceptive Clinical Trials Network program. The $7,374,299.37 task order supports the coordination of clinical trials for novel female contraceptive products, with a period of performance through April 2025. Health Decisions, Inc. is a for-profit clinical research...
- This is a federal contract award from the National Institute of Child Health and Human Development (NICHD) to the Magee-Womens Research Institute And Foundation, a non-profit research organization focused on women's health. The $183,306 contract is for a Phase 1 clinical trial of the Ovaprene vaginal contraceptive device. This award is a delivery order under the $5 million IDIQ contract the institute holds with NICHD to participate in the Contraceptive Clinical Trials Network. The contract has...
- The National Institute of Child Health and Human Development (NICHD) awarded a $432,060 Delivery Order to the University of California, Davis (UC Davis) to finalize the protocol, obtain regulatory approval, and initiate recruitment, screening, and enrollment for a clinical trial of the Ovaprene vaginal device. This Delivery Order is part of NICHD's Contraceptive Development Program and Contraceptive Clinical Trials Network, which focuses on developing new female contraceptive options. The...
- This is a delivery order awarded by the National Institute of Child Health and Human Development (NICHD), a civilian agency within the U.S. Department of Health and Human Services. The contract, valued at $1,420,018.61, is for a multi-center, randomized study to evaluate the pharmacokinetic and pharmacodynamic profile, contraceptive efficacy, and safety of daily oral low-dose ulipristal acetate. The contract was awarded to Essential Access Health, a non-profit organization based in Los...
- This federal contract award was issued by the National Institute of Child Health and Human Development (NICHD), a civilian agency within the U.S. Department of Health and Human Services, to the Magee-Womens Research Institute and Foundation, a non-profit research organization. The $1,585,279 delivery order contract is for a randomized controlled clinical trial to evaluate the efficacy, safety, and acceptability of the C31G female contraceptive. The contract has no set-aside designation and was...
- 75N94020D00015Indefinite Delivery Contract
- 75N94020D00015-75N94023F00001Delivery Order
This is a $349,327 delivery order awarded by the National Institute of Child Health and Human Development (NICHD), a civilian agency, to Essential Access Health, a non-profit organization. The delivery order is for finalizing the protocol, obtaining regulatory approval, and commencing recruitment and enrollment for a clinical trial of the Ovaprene vaginal device. This award is part of a larger $5 million indefinite delivery contract with NICHD to conduct clinical trials and develop protocols in support of the Contraceptive Development Program. Essential Access Health has also received multiple grants from the Department of Health and Human Services to provide family planning and related preventive health services. This contract award is not set aside.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00002 | Other Administrative Action | $0 | 3/26/25 | |
| P00001 | Other Administrative Action | $0 | 9/26/24 | |
| Not listed | Not listed | $349.3k | 9/26/23 |